[1]
|
C. Turesson, W. M. O’Fallon, C. S. Crowson, S. E. Gabriel and E. L. Matteson, “Extra-Articular Disease Manifestations in Rheumatoid Arthritis: Incidence Trends and Risk Factors over 46 Years,” Annals of the Rheumatic Diseases, Vol. 62, No. 8, 2003, pp. 722-727.
doi:10.1136/ard.62.8.722
|
[2]
|
T. Bongartz, C. Nannini, Y. F. Medina-Velasquez, S. J. Achenbach, C. S. Crowson, J. H. Ryu, R. Vassallo, S. E. Gabriel and E. L. Matteson, “Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 62, No. 5, 2010, pp. 1583-1591. doi:10.1002/art.27405
|
[3]
|
C. Nannini, J. H. Ryu and E. L. Matteson, “Lung Disease in Rheumatoid Arthritis,” Current Opinion in Rheumatology, Vol. 20, No. 3, 2008, pp. 340-346.
|
[4]
|
S. V. Kocheril, B. E. Appleton, E. C. Somers, E. A. Kazerooni, K. R. Flaherty, F. J. Martinez, et al., “Comparison of Disease Progression and Mortality of Connective Tissue Disease-Related Interstitial Lung Disease and Idiopathic Interstitial Pneumonia,” Arthritis & Rheumatism, Vol. 53, No. 2, 2005, pp. 549-557.
|
[5]
|
K. Phillips, K. R. Flaherty, E. L. Matteson, T. Bongartz, J. Bathon, K. K. Brown and P. F. Dellaripa, “Interstitial Lung Disease in Rheumatoid Arthritis,” Current Rheu- matology Reviews, Vol. 6, No. 2, 2010, pp. 120-126.
|
[6]
|
C. Turesson and E. L. Matteson, “Extraarticular Features of Rheumatoid Arthritis and Systemic Involvement,” In: M. C. Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt and M. H. Weisman, Eds., Rheumatology, 5th Edition, Mosby, Philadelphia, 2011, pp. 839-847.
|
[7]
|
G. Raghu, H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr, K. K. Brown, et al., “An Official ATS/ERS/JRS/ ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines For Diagnosis and Management,” American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 7, 2011, pp. 788-782.
|
[8]
|
W. A. Wallace, S. E. Howie, A. S. Krajewski and D. Lamb, “The Immunological Architecture of B-Lymphocyte Aggregates in Cryptogenic Fibrosing Alveolitis,” Journal of Pathology, Vol. 178, No. 3, 1996, pp. 323-329.
|
[9]
|
S. R. Atkins, C. Turesson, J. L. Myers, H. D. Tazelaar, J. H. Ryu, E. L. Matteson, et al., “Morphologic and Quantitative Assessment of CD20+ B Cell Infiltrates in Rheumatoid Arthritis-Associated Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia,” Arthritis & Rheumatism, Vol. 54, No. 2, 2006, pp. 6635-6641.
|
[10]
|
C. Turesson, E. L. Matteson, T. V. Colby, Z. Vuk-Pavlovic, R. Vassallo, C. M. Weyand, et al., “Increased CD4+ T cell Infiltrates in Rheumatoid Arthritis-Associated Interstitial Pneumonitis Compared with Idiopathic Interstitial Pneumonitis,” Arthritis & Rheumatism, Vol. 52, No. 1, 2005, pp. 73-79.
|
[11]
|
P. Emery, R.Fleischmann, A. Filiowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, et al., “The Efficacy and Safety of Rituximab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results of a Phase IIB Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial,” Arthritis & Rheumatism, Vol. 54, No. 5, 2006, pp. 1390-1400.
doi:10.1002/art.21778
|
[12]
|
F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mc-Shane, J. F. Fries, N. S. Cooper, et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 31, No. 3, 1988, pp. 315-324.
doi:10.1002/art.1780310302
|
[13]
|
P. W. Jones, “The St George’s Respiratory Questionnaire,” Respiratory Medicine, Vol. 85, No. B, 1991, pp. 25-31.
|
[14]
|
L. A. Saketkoo, E. L. Matteson, K. K. Brown, J. R. Seibold, V. Strand, P. Dellaripa, K. Flaherty, D. Huscher, D. Khanna, C. V. Oddis, K. Phillips, D. Pittrow, A. Wells, C. Denton, O. Distler, A. Fischer, O. Kowal-Bielecka, S. Mittoo and J. Swigris, “Developing Disease Activity and Response Criteria in Connective Tissue Disease-Related Interstitial Lung Disease,” The Journal of Rheumatology, Vol. 38, No. 7, 2011, pp. 1514-1518.
doi:10.3899/jrheum.110281
|
[15]
|
A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers and A. J. K. ?st?r, “Non-Infectious Pulmonary Toxicity of Rituximab: A Systematic Review,” Rheumatology, Vol. 51, No. 4, 2012, pp. 653-662.
doi:10.1093/rheumatology/ker290
|
[16]
|
H. Liote, F. Liote, B. Seroussi, C. Mayaud and J. Cadranel, “Rituximab-Induced Lung Disease: A Systematic Literature Review,” European Respiratory Journal, Vol. 35, No. 3, 2010, pp. 681-687.
doi:10.1183/09031936.00080209
|